{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:38:12Z","timestamp":1792636692035,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1038\/s41409-022-01902-4","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T14:02:56Z","timestamp":1671717776000},"page":"437-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM\/CYVE\/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up"],"prefix":"10.1038","volume":"58","author":[{"given":"Tamim","family":"Alsuliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-5832","authenticated-orcid":false,"given":"Nicolas","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-1713","authenticated-orcid":false,"given":"R\u00e9my","family":"Dulery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sestili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-5875","authenticated-orcid":false,"given":"Zora","family":"Marjanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"1902_CR1","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","volume":"382","author":"V Minard-Colin","year":"2020","unstructured":"Minard-Colin V, Aup\u00e9rin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high-risk, mature B-Cell Non-Hodgkin\u2019s Lymphoma in Children. N Engl J Med. 2020;382:2207\u201319.","journal-title":"N Engl J Med"},{"key":"1902_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood-2017-03-737460","volume":"130","author":"CK Chin","year":"2017","unstructured":"Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130:867\u201374.","journal-title":"Blood."},{"key":"1902_CR3","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","volume":"35","author":"DJ Landsburg","year":"2017","unstructured":"Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. JCO. 2017;35:2260\u20137.","journal-title":"JCO"},{"key":"1902_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","volume":"13","author":"L Wang","year":"2020","unstructured":"Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13:175.","journal-title":"J Hematol Oncol"},{"key":"1902_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1182\/blood-2018-02-778480","volume":"132","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K, Gross TG. Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective. Blood 2018;132:369\u201375.","journal-title":"Blood"},{"key":"1902_CR6","doi-asserted-by":"publisher","first-page":"754964","DOI":"10.3389\/fonc.2021.754964","volume":"11","author":"X Shi","year":"2021","unstructured":"Shi X, Liu X, Li X, Li Y, Lu D, Sun X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021;11:754964.","journal-title":"Front Oncol"},{"key":"1902_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1182\/blood.V128.22.106.106","volume":"128","author":"V Sathyanarayanan","year":"2016","unstructured":"Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, et al. High risk diffuse large B cell lymphoma: a comparison of aggressive subtypes treated with dose adjusted chemotherapy-the university of Texas MD Anderson eExperience. Blood 2016;128:106\u2013106.","journal-title":"Blood"},{"key":"1902_CR8","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","volume":"4","author":"S Lepp\u00e4","year":"2020","unstructured":"Lepp\u00e4 S, J\u00f8rgensen J, Tierens A, Meriranta L, \u00d8stlie I, de Nully Brown P, et al. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020;4:1906\u201315.","journal-title":"Blood Adv"},{"key":"1902_CR9","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1182\/blood.V86.8.2922.2922","volume":"86","author":"J Blay","year":"1995","unstructured":"Blay J, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin\u2019s lymphoma of patients with no known cause of immunosuppression [see comments]. Blood. 1995;86:2922\u20139.","journal-title":"Blood."},{"key":"1902_CR10","unstructured":"Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, et al. Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. haematol [Internet]. 2021 Jul 22 [cited 2022 Jul 20]; Available from: https:\/\/haematologica.org\/article\/view\/haematol.2021.278638"},{"key":"1902_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.annonc.2020.05.016","volume":"31","author":"AK McMillan","year":"2020","unstructured":"McMillan AK, Phillips EH, Kirkwood AA, Barrans S, Burton C, Rule S, et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3\u20135) treated with front-line R-CODOX-M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Ann Oncol. 2020;31:1251\u20139.","journal-title":"Ann Oncol"},{"key":"1902_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41375-020-0766-4","volume":"35","author":"KT Hartert","year":"2021","unstructured":"Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia. 2021;35:522\u201333.","journal-title":"Leukemia."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01902-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01902-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01902-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T06:52:45Z","timestamp":1680677565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01902-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1902"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01902-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}